Pitfalls with Oral Drug Administration in IPF
In the first 3 parts of our blog series on targeted delivery in idiopathic pulmonary fibrosis (IPF), we focused on the potential of inhaled delivery and other targeting strategies to deliver efficacy uplifts for agents as an add-on to the standard of care, while minimising the likelihood of additive side effects. In this fourth installment, we highlight […]
First-in-Human Clinical Trials
The Challenge: TherapeutAix was contacted by an innovative biotech company that was undertaking final preparations for First-in-Human clinical trials. It was known that their biologic has a complex metabolic pathway in vivo. One of the bioanalytical methods needed a major overhaul to be on the same technical level as the rest of the analytical toolbox. […]
Asset for Fibrotic Disease
The Challenge: TherapeutAix was approached by a US-based biotech company to review an asset that they were considering repositioning for fibrotic disease. The company asked for specific help in reviewing existing data, defining the steps then required to take the asset to IND-enabling studies and into the clinic. The Action: The task was to review the […]